[New, in Austria registered specialty drugs. Hivid (2',3'-dideoxycytidine; ddC)].
Töglhofer
W
W
Hoffmann-La Roche Wien Ges.m.b.H.
D000386:AIDS-Related Complex / Q000097:blood / Q000188:drug therapy*; D000163:Acquired Immunodeficiency Syndrome / Q000097:blood / Q000188:drug therapy*; D000818:Animals; D000998:Antiviral Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001317:Austria; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects; D006801:Humans; D007958:Leukocyte Count / Q000187:drug effects; D016047:Zalcitabine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D015215:Zidovudine / Q000097:blood / Q000627:therapeutic use
D000998:Antiviral Agents; D015215:Zidovudine; D016047:Zalcitabine; C050624:2',3'-dideoxycytidinene
Neue, in Osterreich registrierte Spezialitäten. Hivid (2',3'-Dideoxycytidin; ddC).